TumorGen
David has +25 years buy- and sell-side expertise of M&A, partnering and investments within the life sciences and healthcare sectors working within strategic biopharmaceutical companies, private equity, investment banking and venture capital. David holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. He earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College. Additionally, Dr. Crean holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management.
This person is not in any teams
This person is not in any offices
TumorGen
TumorGen is developing a novel drug discovery platform to identify unseen therapeutic targets associated with cancer metastasis. Their patented technology is used to capture circulating metastatic cancer cell clusters (MCCCs).